Introduction
von Hippel-Lindau disease (VHL) is an autosomal dominant familial neoplasia syndrome that results from a germline mutation of the VHL gene on the short arm of chromosome 3. It is characterized by the development of central nervous system (CNS) and visceral lesions. CNS lesions include retinal, cerebellar, brainstem and spinal hemangioblastomas, and endolymphatic sac tumors (ELSTs). Visceral lesions include renal cell carcinomas (RCC), renal cysts, pheochromocytomas, pancreatic cysts and neuroendocrine tumors, as well as cystadenomas of the epididymis and broad ligament (Fig. 1) .
Certainly, from a clinical point of view VHL is a somewhat different condition from classical neurocutaneous diseases (e.g., there are no known associated cutaneous abnormalities; see below). However, from a pathogenic point of view it overlaps with many other well-known neurocutaneous disorders. In addition, it features (and is often first diagnosed because of ) typical ocular "phakomas" and systemic "hamartomas" and tumours. Thus, for these and other reasons (e.g., historical) we have maintained its handling in this book.
Historical perspective and terminology
Although the contribution of von Hippel and Lindau were decisive, many others played an important part in the description of clinical manifestations of VHL (Richard et al. 2004) . In 1872, Jackson first described a cerebellar haemangioblastoma whilst retinal haemangioblastoma was described by Panas and Rémy in 1879 (Richard et al. 2004) . The first recorded case of a probable patient with VHL was a 35-year-old woman who died in 1864 with eye and brain tumors (Galezowski 1987) . In 1885, PyeSmith showed that a cerebellar cystic tumor was associated with several renal and pancreatic cysts (Richard et al. 2004 ). The first histological description of VHL is credited to Edward Treacher Collins , an eminent British ophthalmologist at the Royal London Eye Hospital, Moordfields, who described bilateral retinal haemangioblastomas of enucleated eyes from two affected siblings in 1894 (Collins 1894). He judged the retinal lesions to be true vascular neoformations, which he named capillary nevus (Beighton and Beighton 1986, Richard et al. 2004) .
Eugen Von Hippel (1867-1939) was born in Konigsberg (non Kaliningrad), Germany, son of Arthur von Hippel (1841 Hippel ( -1916 professor of ophthalmology in that town and a pioneer in the field of corneal grafting (Beighton and Beighton 1986). Eugen received his MD in Gottingen in 1890 and two years later endeavored his specialization in ophthalmology with Theodore von Leber becoming professor of ophthalmology at Halle, Germany, at the turn of the century. He gained international recognition for his work on the pathological anatomy and congenital malformations of the eye. In 1895, he first described the fundoscopy findings in the eye of a 23-year-old man, Otto Mayer, who had presented two years earlier with visual loss (Von Hippel 1896). In 1904, presented further details on the same patient, who had developed three additional retinal lesions, as well as another similar case of a 28-year-old patient (Von Hippel 1904) , and after careful analysis of the histological characteristics of the right eye of patient Mayer concluded, in 1911, that the retinal lesion was a congenital cystic capillary angiomatosis which he termed angiomatosis retinae (Richard et al. 2004 , Von Hippel 1911 .
In 1921, Brandt published autopsy results of the 47-year-old Mayer died after having had various neurological disturbances: he was found to also have tumors of the cerebellum and conus medullaris, and the different features of VHL into a single recognizable entity. In a 1928 monograph, Cushing and Bailey provided detailed descriptions of 11 patients with what they described as "Lindau's disease". These descriptions included detailed clinical, surgical and histopathological findings (Cushing 1928) . Later, in 1936, Davison honored both von Hippel and Lindau by giving VHL the name it bears today (Davison 1936) . In 1964, Melmon and Rosen published the first major review with diagnostic criteria for VHL (Melmon and Rosen 1964) . The VHL gene was fully identified and cloned in 1993 (Latif et al. 1993 ).
Incidence and prevalence
VHL has an incidence of 1 in 36,000 people (Maher et al. 1991) . Penetrance is nearly complete by the age of 60 years (Maher et al. 1990 ). Maher et al. estimated that 84%, 70%, and 69% of VHL patients will develop cerebellar hemangioblastoma, retinal hemangioblastoma, or renal cell carcinoma, respectively, by age 60 (Maher et al. 1990 ). Because it is an autosomal dominant transmitted syndrome, males and females are affected equally.
Childhood presentations of VHL
There are no distinct pediatric presentations of VHL. Many pediatric cases are discovered during genetic testing of family members of VHL patients, and are treated similarly to adult cases.
Clinical manifestations Skin abnormalities
There are no known associated cutaneous lesions.
Nervous system abnormalities

CNS Hemangioblastomas
General Features. CNS hemangioblastomas in VHL are often multiple, and most often arise in the cerecystic lesions of the kidneys, pancreas, and epididymis (Brandt 1921).
However, it was Arvid Lindau (1892-1958), in 1926, that 
